Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors

WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 16, 2019-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ripretinib, the...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news